What Would Break First If Medical Trend Kept Outpacing Treaty Economics?

The Board Question That Exposes a Blind Spot in Trend Monitoring

Most board risk committees review historical loss ratios and current capital adequacy as a matter of routine. Fewer ask the forward-looking question that actually matters for a risk like medical trend outpacing treaty economics: if this trend persisted at current levels for several more years, what breaks first, and on which treaties?

That single question, asked directly and answered with specific treaty-level detail, does more to surface this risk at the governance level than any amount of historical reporting. Historical reporting, by definition, only shows what has already happened.

For directors sitting on a risk committee, this question costs nothing to ask and reveals immediately whether management's monitoring is built for the tail case or only for business as usual.

Board-level oversight of this kind only works if the underlying operating control already exists, the process covered in from fragmented evidence to executive control over medical trend, and the same governance logic applies directly to longevity concentration across pension transactions, a related risk many of the same boards also oversee.

What Would Break First If Medical Trend Kept Outpacing Treaty Economics for Several More Years?

Capital adequacy on the most trend-exposed treaties would typically break first, since reserve inadequacy compounds every reporting period before it fully shows up in reported earnings.

Capital adequacy metrics are more sensitive to a persistent trend gap than reported earnings, because capital models are built to respond to reserve adequacy signals directly, while earnings only reflect the portion of the gap that has already worked its way through claims development. This means the earliest visible strain from a sustained trend gap tends to show up as a capital metric moving toward a threshold, well before it shows up as a disappointing earnings result.

That dynamic is covered in more depth from the capital-management angle in the capital drag created by medical trend outpacing treaty economics.

Why Does a Board Need to Ask This Question Rather Than Trust Management's Monitoring?

Boards are responsible for confirming risk appetite limits are actually being tested against realistic scenarios, not just assuming management's routine monitoring already covers the tail case.

Management's day-to-day monitoring is typically built around routine thresholds and expected-case scenarios, which is appropriate for operational purposes but is not the same as testing what happens under a sustained, elevated trend environment. The board's governance role is specifically to ask whether that tail scenario has actually been tested, rather than assuming it has been.

Routine monitoring and stress testing serve different purposes, and one does not automatically imply the other has been done.

What Is a Stress Scenario a Board Should Specifically Request?

A multi-year projection showing capital position if current elevated medical trend, in the 8.5% to 9.5% range seen in 2026, persisted for three to five more years without repricing.

This is a concrete, answerable request rather than an abstract one. PwC's 2026 medical trend survey and Aon's separate 2026 projection both point to trend in the high single digits persisting for a third or fourth consecutive year, which gives a board a realistic, evidence-based scenario to request rather than an arbitrary hypothetical.

Asking management to project capital position under that specific persistence scenario, rather than a generic "what if trend rises" question, produces a far more useful answer. A board that receives this projection annually, alongside its regular capital adequacy report, has a built-in early warning it did not have before. A Capital Requirement Estimation AI Agent can generate the underlying persistence-scenario capital figures management would need to answer this request on demand.

How Does Risk Appetite Connect to This Specific Exposure?

Risk appetite statements typically set limits on capital adequacy and earnings volatility, and a persistent trend gap tests both limits simultaneously, so the board needs to see it against those explicit thresholds.

A risk appetite statement is only useful if the board can see current and projected exposure measured directly against its stated limits. A trend gap that is quietly eroding both capital adequacy and earnings stability needs to be shown against those specific numeric thresholds, not described in general terms, so the board can judge how much appetite headroom actually remains before either limit is breached.

What Governance Gap Most Commonly Lets This Risk Go Unmonitored at the Board Level?

Board reporting that presents only historical loss ratios, without a forward-looking trend-versus-pricing view, gives the board a lagging picture instead of the leading indicator it actually needs.

This is the same structural problem seen at the operating level, where fragmented data prevents an early diagnosis, except it recurs at the governance level as a reporting gap rather than a data gap. A board that only ever sees historical loss ratios is structurally unable to catch a trend problem before it has already materialized, no matter how attentive the individual board members are, because the information they are given simply does not contain a leading indicator.

Should This Be a Standing Board Agenda Item or a One-Time Review?

It should be a standing item within existing risk committee reporting, reviewed on the same cadence as other capital adequacy metrics, not a one-time deep dive.

A one-time review answers the question for a single point in time and then goes stale as claims experience and trend conditions keep evolving. Embedding the trend-versus-pricing view into the standing risk committee reporting cycle, alongside existing capital adequacy metrics, keeps the board's picture current and ensures the question gets asked again automatically rather than depending on someone remembering to raise it.

What Should a Board Briefing on This Risk Actually Contain?

A useful board briefing on this risk fits on one page: current trend versus priced trend by major treaty, the dollar capital impact of the gap, and a named owner with a recommended action.

It should name which specific treaties are furthest from their priced trend assumption, not describe the portfolio in aggregate, since aggregate figures hide exactly the concentrated exposures a board needs to see. It should show the stress scenario, trend persisting at 2026 levels for three to five years, translated into a capital position number, not a narrative description.

A briefing built this way takes a risk committee minutes to absorb and gives directors something concrete to question, rather than a general assurance that trend is "being monitored."

The board's job is not to run the trend calculation itself, it is to make sure the calculation exists, gets reviewed on a fixed schedule, and gets measured against explicit risk appetite thresholds rather than described qualitatively. A board that asks what breaks first, and gets a specific, treaty-level answer, has functioning oversight.

A board that only reviews last year's loss ratio has a reporting routine, not oversight of the risk that actually matters.

Why Should Rating Agency Perspective Factor Into This Oversight?

Rating agencies assess reserve adequacy and capital strength as core inputs to a reinsurer's rating, which means a persistent, unaddressed trend gap is exactly the kind of finding that can surface in a ratings review before it surfaces internally.

A board that has already stress-tested and quantified this exposure is in a materially stronger position during a ratings conversation than one relying on management's assurance that trend is "being watched." Demonstrating a standing, board-reviewed process for this specific risk, with defined thresholds and documented escalation, is the kind of governance evidence rating agencies look for when assessing enterprise risk management maturity.

Boards that treat this oversight as purely an internal risk exercise are missing that external stakeholders, rating agencies especially, are evaluating the same underlying discipline from outside.

Sources

• HFMA, citing PwC's 2026 medical cost trend survey: "Healthcare costs for businesses to rise 8.5% in 2026"
• Aon: "U.S. Employer Health Care Costs Expected to Rise 9.5 Percent in 2026"